Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Total Current Assets
All assets expected to be converted to cash or used up within one year.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 282.0% from a year ago
Total current assets stood at $10.51M at the end of Q1 FY2026, up 282.0% from a year earlier and up 255.9% from the prior quarter.
Context
- Total current assets amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +282.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- (6.74M) USD
- Year-over-year change
- -264.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.74M) | -264.7% |
| FY2024 | 2024-12-31 | 4.09M | -41.5% |
| FY2023 | 2023-12-31 | 6.99M | -48.1% |
| FY2022 | 2022-12-31 | 13.47M | -50.5% |
| FY2021 | 2021-12-31 | 27.2M | — |
Total Current Assets vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +282.0% is the 3rd highest of 9, against a peer median of +23.2%.
- Total current assets amounts to 100.0% of total assets for GLSI, versus a peer median of 93.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $181.59M USD | -28.9% | -22.6% | 66.7% | |
| Mar 2026 | $113.95M USD | +7.5% | +4.0% | 94.4% | |
| Mar 2026 | $95.28M USD | +311.8% | -14.5% | 51.1% | |
| Mar 2026 | $92.27M USD | +449.9% | +89.4% | 96.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $66.6M USD | +39.0% | +0.7% | 99.7% |
| Mar 2026 | $35.81M USD | +56.6% | +0.2% | 99.1% | |
| Mar 2026 | $10.51M USD | +282.0% | — | 100.0% | |
| Mar 2026 | CA$7.49M CAD | -59.5% | -35.9% | 91.7% | |
| Mar 2026 | $6.98M USD | -51.3% | -32.1% | 23.5% | |
| Peer median (excluding GLSI) | — | +23.2% | -7.1% | 93.1% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.